Rafferty Asset Management LLC Purchases 6,154 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)

Rafferty Asset Management LLC lifted its stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE) by 8.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 76,740 shares of the company’s stock after purchasing an additional 6,154 shares during the quarter. Rafferty Asset Management LLC owned about 0.15% of Spyre Therapeutics worth $1,787,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in SYRE. Huntington National Bank bought a new stake in shares of Spyre Therapeutics in the 4th quarter worth approximately $34,000. Mirae Asset Global Investments Co. Ltd. bought a new position in Spyre Therapeutics in the 4th quarter valued at approximately $46,000. KLP Kapitalforvaltning AS bought a new position in Spyre Therapeutics in the 4th quarter valued at approximately $182,000. Tower Research Capital LLC TRC lifted its position in Spyre Therapeutics by 1,548.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,574 shares of the company’s stock valued at $200,000 after acquiring an additional 8,054 shares in the last quarter. Finally, Arizona State Retirement System lifted its position in Spyre Therapeutics by 38.4% in the 4th quarter. Arizona State Retirement System now owns 10,115 shares of the company’s stock valued at $235,000 after acquiring an additional 2,805 shares in the last quarter. 80.39% of the stock is owned by institutional investors.

Spyre Therapeutics Price Performance

NASDAQ:SYRE opened at $15.40 on Wednesday. The firm has a market capitalization of $928.25 million, a price-to-earnings ratio of -2.06 and a beta of 2.78. Spyre Therapeutics, Inc. has a one year low of $10.91 and a one year high of $40.26. The business has a fifty day moving average price of $14.79 and a 200-day moving average price of $21.13.

Spyre Therapeutics (NASDAQ:SYRE) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.74) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.02. On average, equities research analysts expect that Spyre Therapeutics, Inc. will post -4.46 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on SYRE shares. Leerink Partners started coverage on Spyre Therapeutics in a research report on Tuesday, April 8th. They issued an “outperform” rating and a $45.00 price objective on the stock. Wolfe Research assumed coverage on Spyre Therapeutics in a research report on Tuesday, March 18th. They issued an “outperform” rating and a $27.00 price objective on the stock. Wedbush reiterated an “outperform” rating and set a $65.00 target price on shares of Spyre Therapeutics in a research note on Monday, May 5th. The Goldman Sachs Group upgraded shares of Spyre Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 18th. Finally, Leerink Partnrs upgraded shares of Spyre Therapeutics to a “strong-buy” rating in a research note on Tuesday, April 8th. Six investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $53.40.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).